Iron gets trapped inside cells, accumulating faster than mitochondria can use it
As the brain ages, its ancient capacity to regulate iron quietly fails, allowing a toxic accumulation that corrodes the very machinery of thought and memory. Researchers at Northwestern Medicine have traced this deterioration to a hormonal imbalance deep within aging neurons — a discovery that may help explain not only the ordinary forgetting of old age, but the more devastating losses of Parkinson's and Alzheimer's disease. In identifying the mechanism, they have also glimpsed a possible remedy, one already being tested in human trials.
- Iron, essential to life in careful measure, becomes a slow poison in the aging brain — accumulating in both the cytoplasm and mitochondria in a pattern seen in no other organ studied.
- A hormone called hepcidin, normally a liver-based regulator of iron balance, is dramatically overproduced in the aging brain cortex, trapping iron inside neurons where it generates toxic oxidative stress.
- The mitochondria — the cell's energy engines — are overwhelmed by the excess iron faster than they can process it, triggering the cellular damage associated with cognitive decline and neurodegenerative disease.
- Scientists are now pursuing iron chelators as a therapeutic strategy, but face a formidable obstacle: most compounds that bind and neutralize iron cannot cross the blood-brain barrier.
- At least one chelator can breach that barrier, and a clinical trial for Parkinson's disease is already underway — offering the first human test of whether reversing iron accumulation can protect the aging brain.
As the brain ages, its ability to regulate iron breaks down — and Northwestern Medicine researchers have now identified the mechanism behind that failure, publishing their findings in eLife. The discovery may help explain why memory dims with age and why diseases like Parkinson's and Alzheimer's take hold.
In healthy, younger organisms, iron levels inside cells are tightly balanced. With age, that balance slips. The brain becomes uniquely vulnerable: it is the only organ the research team observed accumulating excess iron in both the cytoplasm and the mitochondria simultaneously. Other organs did not show this pattern.
The key culprit appears to be hepcidin, a hormone the liver normally uses to manage iron throughout the body. In the aging brain cortex, hepcidin is dramatically overexpressed. There, it blocks ferroportin — the protein responsible for exporting iron out of neurons. With that exit sealed, iron builds up inside cells and overwhelms the mitochondria, generating oxidative stress and cellular damage. Why hepcidin surges with age remains unclear, though inflammation and increased activity of a protein called transferrin receptor 2 may be involved.
The finding points toward a therapeutic possibility. If brain-derived hepcidin could be suppressed, iron levels might be restored to healthier levels. Iron chelators — compounds that bind iron and render it inert — are one avenue already being explored for heart disease. The challenge is crossing the blood-brain barrier, which blocks most such compounds. But at least one chelator can make that crossing, and it is currently being evaluated in a clinical trial for Parkinson's disease — a first real test of whether this strategy can protect the human brain from its own slow accumulation of iron.
As the brain ages, iron accumulates in ways that damage cells and may explain why memory falters and neurodegenerative diseases take hold. Researchers at Northwestern Medicine have identified the mechanism behind this buildup, and their findings, published in eLife, point toward a possible treatment.
The culprit is a breakdown in the brain's ability to regulate iron. In younger organisms, iron homeostasis—the balance of iron in and out of cells—is tightly controlled. But as years pass, that control slips. The result is oxidative stress: cells lose their capacity to neutralize reactive oxygen species, toxic byproducts of normal metabolism. Iron accumulation appears to be a significant source of this stress in the brain, according to Hossein Ardehali, a cardiologist and molecular researcher at Northwestern who led the study.
To understand what was happening, Ardehali and his team, including lead author Tatsuya Sato, compared young and aged mice, measuring iron levels in different cellular compartments throughout the body. The brain stood out. It was the only organ they examined that showed increased iron in both the cytoplasm and the mitochondria as the animals grew older. Other organs did not display this pattern.
The researchers then looked at which genes were being activated. They found that hepcidin—a hormone normally produced by the liver to manage iron throughout the body—was dramatically overexpressed in the brain cortex of older animals. In the brain, hepcidin's role takes on new significance: it blocks ferroportin, a protein that normally exports iron from neurons. When hepcidin is overactive, iron gets trapped inside cells. It accumulates in the mitochondria, the cellular powerhouses, faster than the organelles can use it. The excess iron then triggers damage.
The exact reason hepcidin expression ramps up with age is not yet clear, though age-related inflammation and increased activity of a protein called transferrin receptor 2 may play a role. What matters is that this mechanism could explain some of the cognitive decline people experience as they grow older, and it may contribute to diseases like Parkinson's and Alzheimer's.
The finding opens a therapeutic door. If researchers could suppress the overproduction of brain-derived hepcidin, they might be able to restore normal iron levels and slow cognitive decline. One approach already being tested involves iron chelators—compounds that bind to iron and render it biologically unavailable. These are currently being studied for heart disease. The challenge is getting them into the brain: most chelators cannot cross the blood-brain barrier, the selective membrane that protects the brain from unwanted substances. But at least one chelator can make the crossing, and it is already being tested in a clinical trial for Parkinson's disease. That trial may offer the first real evidence of whether this strategy works in humans.
Notable Quotes
If we can restore intracellular iron levels via suppressing this brain-derived hepcidin, we might be able to improve age-related cognitive decline— Tatsuya Sato, lead author, Sapporo Medical University
This is likely a key player in iron accumulation in the aged brain— Tatsuya Sato, on hepcidin's role
The Hearth Conversation Another angle on the story
Why does the brain accumulate iron differently than other organs as we age?
The brain has its own iron regulation system, and that system breaks down. Hepcidin, a hormone that normally helps manage iron throughout the body, gets overproduced in the aging brain. When it does, it traps iron inside neurons by blocking the protein that would normally export it. Other organs don't seem to have this problem.
So it's not that the brain gets more iron from the bloodstream—it's that the brain can't get rid of what it has?
Exactly. The iron is being locked in. And because mitochondria can only use so much iron, the excess sits there and generates oxidative stress, which damages the cell.
Is this definitely what causes Alzheimer's and Parkinson's, or is it just one piece?
It's likely one piece of a larger puzzle. But it's a piece that appears in aging brains generally, not just in people with disease. So it may explain why cognitive decline happens to many of us, and why some people develop neurodegenerative disease.
If you could block hepcidin in the brain, would that solve the problem?
That's the hypothesis. If you could suppress it, you might restore normal iron export and prevent the accumulation. But you'd have to be careful—iron is essential for brain function. You can't just remove it all.
And the chelators—how close are we to knowing if they actually work?
There's already a clinical trial running in Parkinson's patients. That will tell us whether the theory translates to real benefit. The hard part was finding a chelator that could cross the blood-brain barrier. They found one. Now we wait.